DrugDashboards

Meropenem

Meropenem · MEROPENEM 1 g/20mL · Injection, Powder, For Solution · Intravenous · Fresenius Kabi USA, LLC

NDC 63323-0508-30 · 10 VIAL in 1 CARTON / 20 mL in 1 VIAL · ANDA · View full market →

The short version

8 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 12% over the past year, to $4.67 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$4.67per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$0.3250per billing unit (100 MG)HCPCS J2185 · Jul 1, 2026
  • Part D plans paid (avg)$4.31per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$50.32per package of 10X30MLFresenius Kabi, LLC · May 15, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$5.00$10.00Apr 2024Sep 2026$4.67
30 price points · per EASource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$59.00
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 100 MG
$0.325
HCPCS J2185 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$98,149
1,915 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for meropenem (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $185.36 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA091404
TE code
AP
Approval date
Oct 26, 2011
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Meropenem (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCMEROPENEM 1 g/20mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.MEROPENEM 500 mg/10mLAug 13, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.MEROPENEM 1 g/20mLAug 13, 2026Sep 3, 2026
Hospira, Inc.MEROPENEM 500 mg/10mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Eugia US LLCMEROPENEM 500 mg/1Jul 15, 2026Sep 2, 2026
Eugia US LLCMEROPENEM 1 g/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCMEROPENEM 500 mg/10mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsMEROPENEM 1 g/30mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsMEROPENEM 500 mg/20mLJul 15, 2026Sep 2, 2026
WG Critical Care, LLCMEROPENEM 2 g/1Jul 15, 2026Sep 2, 2026
Xellia Pharmaceuticals USA LLCMEROPENEM 500 mg/1Jul 15, 2026Sep 2, 2026
Xellia Pharmaceuticals USA LLCMEROPENEM 1 g/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.MEROPENEM 1 g/20mLJul 15, 2026Aug 31, 2026
WG Critical Care, LLCMEROPENEM 500 mg/1Jul 15, 2026Aug 28, 2026
WG Critical Care, LLCMEROPENEM 1 g/1Jul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Meropenem — NDC 63323-0508-30," retrieved September 3, 2026, https://drugdashboards.com/drug/63323050830.

Free to cite with attribution — see how the data is put together.